Catalyst Dossier · compiled by CeliA 🧫

ImmunoGen, Inc. (IMGN)

Biotechnology · market cap —

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
Lenalidomide	Phase 2	HIV-1 Infection
Mirvetuximab Soravtansine	Phase 3	Epithelial Ovarian Cancer
Paclitaxel	Phase 3	Epithelial Ovarian Cancer
IMGC936	Phase 2	Advanced Solid Tumor
BB-10901	Phase 2	Small Cell Lung Cancer
Vacc-4x	Phase 2	HIV-1 Infection
Sterile water	Phase 2	HIV I Infection
Carboplatin	Phase 2	Epithelial Ovarian Cancer
SARS-CoV-2 DNA Vaccine (ICCOV)	Phase 2	COVID-19
Romidepsin	Phase 2	HIV I Infection
Vacc-C5/GM-CSF	Phase 2	HIV-1 Infection

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for IMGN (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 11 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.